Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Optimi Health Corp
(OP:
OPTHF
)
0.2278
UNCHANGED
Streaming Delayed Price
Updated: 1:54 PM EST, Feb 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Optimi Health Corp
< Previous
1
2
3
Next >
Optimi Health Announces C$3.27 Million Private Placement with Strategic Investment from Lululemon Founder Chip Wilson
October 12, 2022
Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP-grade psilocybin, synthetic psychedelic substances and...
Via
PressReach
Optimi Closes Non-Brokered Private Placement, Here Are The Details
↗
October 11, 2022
Canadian licensed producer of GMP-grade psilocybin Optimi Health Corp.
Via
Benzinga
Psychedelic Drugs Prove Their Worth In Clinical Trials
October 11, 2022
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial...
Via
PressReach
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
October 05, 2022
A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll...
Via
PressReach
Topics
Cannabis
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
October 05, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,...
Via
FinancialNewsMedia
Topics
Cannabis
Two Psychedelics Companies Will Study Effects Of Natural Psilocybin And MDMA In Healthy Volunteers
↗
September 22, 2022
Health Canada receives applications concerning clinical trials on a regular basis. This time, the licensed producer of natural EU-GMP psilocybin and MDMA Optimi Health Corp.
Via
Benzinga
Optimi Health and ATMA Journey Centers to Send a Clinical Trial Application to Health Canada for Phase I Natural Psilocybin and MDMA
September 22, 2022
Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a Canadian company that makes natural, scalable, and easy-to-get psychedelic and functional mushrooms, as well as synthetic formulations, to help people...
Via
PressReach
Topics
Supply Chain
Psychedelic Mushrooms Are Going Global: Supply Deal With UK-Based Wellness Company Moves Forward
↗
September 07, 2022
Expert functional and magic mushrooms grower Optimi Health Corp. (OTCQX: OPTHF) has signed an agreement with Avida Global, a privately-held UK-based producer of white label products including...
Via
Benzinga
Psychedelics May Make People Less Afraid of Death
September 07, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 7, 2022 – According to a new survey by Johns Hopkins Medicine researchers, people’s attitudes toward death change...
Via
FinancialNewsMedia
Topics
Supply Chain
New Biosynthetic Psilocybin Hits The Psychedelics Market, Available For Research And Clinical Trials
↗
September 02, 2022
With psilocybin among the favorites within psychedelics,
Via
Benzinga
Magic Mushrooms Producer Optimi Keeps Betting On The FDA-approval Of Psychedelics
↗
September 01, 2022
Optimi Health (OTCQX: OPTHF) has released an operational update on its planned year of commercialization, including the launch of psychedelics catalog.
Via
Benzinga
Psychedelics Use Among Young Adults Reaches All-Time High
September 01, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 1, 2022 – Young adults are using more hallucinogens than ever. According to a National Institute of Health survey,...
Via
FinancialNewsMedia
First International Psilocybin Supply Agreement For Optimi Health: Here Are The Details
↗
August 30, 2022
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian-based company licensed by Health Canada to produce and supply natural psilocybin and other psychedelic substances, announced that...
Via
Benzinga
Optimi Health Given Green Light To Produce And Distribute MDMA In Canada, The Legal Landscape Ahead
↗
August 16, 2022
Optimi Health Corp.
Via
Benzinga
Meet Blue Serenity, Canada's First Natural Therapeutic Psilocybin Product For Approved Patients
↗
August 10, 2022
The Canadian-based company licensed by Health Canada for psychedelic and functional mushrooms production, Optimi Health Corp.
Via
Benzinga
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression
August 10, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – August 10, 2022 – Toronto’s Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study...
Via
FinancialNewsMedia
Topics
Supply Chain
What A Collab! Optimi Health & Patient Advocate Thomas Hartle's New Medical Psilocybin Venture
↗
August 08, 2022
Optimi Health Corp.
Via
Benzinga
New Optimi Supply Agreement: Psilocybin For Phase 1 Trial On Microdosing For Wellbeing, No Hallucinogenic Effects
↗
July 13, 2022
Canadian psychedelics company Optimi Health Corp. (OTCQX: OPTHF) signed a supply agreement with the Bloom Psychedelic Therapy And Research Centre, a Calgary-based provider of psychedelic-assisted...
Via
Benzinga
HAVN Life Sciences & Optimi Health Corp Announce Supply Agreements, Here Are The Details
↗
June 28, 2022
Two publicly traded psychedelics companies announced supply agreements. HAVN Life Sciences (OTC: HAVLF) will provide mental health clinic MPB Group Inc. with psilocybin-containing mushrooms for its...
Via
Benzinga
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
↗
June 15, 2022
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider.
Via
Benzinga
Shrooms Move Forward For Palliative Care, Optimi To Supply High-Grade Psilocybin For Private Mental Health Practitioner In CA
↗
June 08, 2022
Optimi Health Corp.
Via
Benzinga
Optimi Health Signs Two New Supply Agreements In Less Than a Week
↗
May 31, 2022
Optimi (OPTHF), the Canadian, home-grown mushroom formulations producer has signed not one but two supply deals with different research companies.
Via
Benzinga
Optimi Completes First Grow of Psilocybin Mushrooms, Introduces New Head Of Cultivation
↗
May 25, 2022
Optimi Health Corp. (OPTHF), the Canadian company that produces homegrown and scalable mushrooms accessible to all, announces big step towards commercialization. It has successfully completed its first...
Via
Benzinga
Psyched: Medical Psychedelics In Davos, Canadian Sen Does Psychedelics, Ei.Ventures & Mycotopia To Merge Into $383M Company
↗
May 24, 2022
Medical Psychedelics have made it into Davos, just in time for the World Economic Forum.
Via
Benzinga
Optimi Health Adds Large Portfolio Of Magic Mushrooms Strains To Its Genetic Bank
↗
May 18, 2022
Optimi Health Corp (OTCQX: OPTHF) acquired thirty-three types of psilocybin and mushroom strains intended for cultivation.
Via
Benzinga
Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application
October 05, 2021
Company utilizes green chemistry to stabilize natural product with higher yields Vancouver, BC – October 5, 2021 – Optimi Health Corp. (OTCQB: OPTHF) (CSE: OPTI) (FRA: 8BN) (“Optimi” or the “Company”),...
Via
FinancialNewsMedia
Topics
Intellectual Property
Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market
July 07, 2021
Via
FinancialNewsMedia
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
↗
October 18, 2021
The Week In Psychedelics
Via
Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
↗
October 13, 2021
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...
Via
Benzinga
Why North America Region is Dominating the Billion Dollar Psychedelic Drugs Market
October 05, 2021
Palm Beach, FL – October 5, 2021 – FinancialNewsMedia.com News Commentary – The psychedelic drugs market is creating major potential for treatment of mental illnesses, and as a result, it is likely to...
Via
FinancialNewsMedia
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.